Global Chemotherapy Market

Chemotherapy Comprehensive Study by Type (Alkylating Agents, Anti-metabolites, Plant Alkaloids and Terpenoids, Podophyllotoxin, Taxanes, Topoisomerase Inhibitor, Anti-Tumour Antibiotics, Hormones, Monoclonal Antibodies, Others), Route of Administration (Intravenous, Oral, Subcutaneous, Intra-Muscular, Intravesicular, Topical, Intraperitoneal, Intraventricular/Intrathecal), Indication (Oncology/Cancer, Bone Marrow Diseases, Immune System Disorders, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Others), Dosage Form (Capsule, Tablets, Injections, Others), Drug Class (Alkylating Agents, Mitotic Inhibitors, Antimetabolites, Topoisomerase Inhibitors, Antitumor Antibiotic) Players and Region - Global Market Outlook to 2030

Chemotherapy Market by XX Submarkets | Forecast Years 2024-2030  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
About Chemotherapy
The chemotherapy is an aggressive form of chemical drug therapy meant to destroy rapidly growing cells in the body. It is generally used to treat the caner in which cancerous cell multiply faster than other cells. It is used in the combination with other therapies including surgery, radiation or hormone therapy. It has three main goals for chemotherapy includes cure, control and palliation of the cancer. The drugs used in the chemotherapy prevent cell division, targets the food sources of cancer cells such as the enzymes and hormones and triggers apoptosis.

AttributesDetails
Study Period2018-2030
Base Year2023
UnitValue (USD Million)


The market is highly competitive with the active presence of dominant players. The companies are exploring the market by adopting mergers & acquisitions, expansions, investments, new service launches and collaborations as their preferred strategies. The players are exploring new geographies through expansions and acquisitions to avail a competitive advantage through combined synergies. Analyst at AMA Research estimates that Global Players will contribute the maximum growth to Global Chemotherapy market throughout the forecasted period. Established and emerging Players should take a closer view at their existing organizations and reinvent traditional business and operating models to adapt to the future.

Novartis AG (Switzerland), Pfizer Inc. (United States), Johnson & Johnson Services Inc. (United States), Bristol-Myers Squibb Company (United States), GlaxoSmithKline PLC (United Kingdom), Eli Lilly and Company (United States), F. Hoffmann-La Roche Ltd (Switzerland), Merck & Co. Inc. (United States), Sanofi S.A. (France) and Celgene Corporation (United States) are some of the key players that are part of study coverage. Additionally, the Players which are also part of the research coverage are LEO Pharma A/S (Denmark), Bausch Health Companies Inc. (Canada), Sun Pharmaceutical Industries Ltd. (India), Aurobindo Pharma (India) and Hikma Pharmaceuticals PLC (U.K.),.

Segmentation Overview
AMA Research has segmented the market of Global Chemotherapy market by Type (Alkylating Agents, Anti-metabolites, Plant Alkaloids and Terpenoids, Podophyllotoxin, Taxanes, Topoisomerase Inhibitor, Anti-Tumour Antibiotics, Hormones, Monoclonal Antibodies and Others) and Region.



On the basis of geography, the market of Chemotherapy has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). If we see Market by Route of Administration, the sub-segment i.e. Intravenous will boost the Chemotherapy market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by Indication, the sub-segment i.e. Oncology/Cancer will boost the Chemotherapy market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by Distribution Channel, the sub-segment i.e. Hospital Pharmacy will boost the Chemotherapy market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by Dosage Form, the sub-segment i.e. Capsule will boost the Chemotherapy market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by Drug Class, the sub-segment i.e. Alkylating Agents will boost the Chemotherapy market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.

Influencing Trend:
Rising demand for personalized medicines

Market Growth Drivers:
Increasing prevalence of cancer and Increasing investment for healthcare infrastructure

Challenges:
High Development Costs

Restraints:
Toxicity and Side Effects

Opportunities:
Development of innovative technology of chemotherapy and Increase in the number of research and development activities

Market Leaders and their expansionary development strategies
In April 2023, BioNTech SE and Duality Biologics (Suzhou) Co. Ltd.announced collaboration agreements for two ADC assets to develop, manufacture and commercialize the two assets with this collaboration, ADCs will become an additional drug class in BioNTech’s oncology portfolio with the aim to further support BioNTech’s mission of developing highly efficacious therapies for cancer patients at every stage of disease.
In May 2022, Gland Pharma had announced the launch of Bortezomib for Injection in US market. Bortezomib for injection is employed for treating certain types of cancer including multiple myeloma and mantle cell lymphoma.


Key Target Audience
Chemotherapy Drug Manufacturers, Research Professionals, Emerging Companies, Government Body & Associations and End-user

About Approach
To evaluate and validate the market size various sources including primary and secondary analysis is utilized. AMA Research follows regulatory standards such as NAICS/SIC/ICB/TRCB, to have a better understanding of the market. The market study is conducted on basis of more than 200 companies dealing in the market regional as well as global areas with the purpose to understand the companies positioning regarding the market value, volume, and their market share for regional as well as global.

Further to bring relevance specific to any niche market we set and apply a number of criteria like Geographic Footprints, Regional Segments of Revenue, Operational Centres, etc. The next step is to finalize a team (In-House + Data Agencies) who then starts collecting C & D level executives and profiles, Industry experts, Opinion leaders, etc., and work towards appointment generation.

The primary research is performed by taking the interviews of executives of various companies dealing in the market as well as using the survey reports, research institute, and latest research reports. Meanwhile, the analyst team keeps preparing a set of questionnaires, and after getting the appointee list; the target audience is then tapped and segregated with various mediums and channels that are feasible for making connections that including email communication, telephonic, skype, LinkedIn Group & InMail, Community Forums, Community Forums, open Survey, SurveyMonkey, etc.

Report Objectives / Segmentation Covered

By Type
  • Alkylating Agents
  • Anti-metabolites
  • Plant Alkaloids and Terpenoids
  • Podophyllotoxin
  • Taxanes
  • Topoisomerase Inhibitor
  • Anti-Tumour Antibiotics
  • Hormones
  • Monoclonal Antibodies
  • Others
By Route of Administration
  • Intravenous
  • Oral
  • Subcutaneous
  • Intra-Muscular
  • Intravesicular
  • Topical
  • Intraperitoneal
  • Intraventricular/Intrathecal

By Indication
  • Oncology/Cancer
  • Bone Marrow Diseases
  • Immune System Disorders
  • Others

By Distribution Channel
  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Pharmacy
  • Others

By Dosage Form
  • Capsule
  • Tablets
  • Injections
  • Others

By Drug Class
  • Alkylating Agents
  • Mitotic Inhibitors
  • Antimetabolites
  • Topoisomerase Inhibitors
  • Antitumor Antibiotic

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Increasing prevalence of cancer
      • 3.2.2. Increasing investment for healthcare infrastructure
    • 3.3. Market Challenges
      • 3.3.1. High Development Costs
    • 3.4. Market Trends
      • 3.4.1. Rising demand for personalized medicines
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Chemotherapy, by Type, Route of Administration, Indication, Distribution Channel, Dosage Form, Drug Class and Region (value) (2018-2023)
    • 5.1. Introduction
    • 5.2. Global Chemotherapy (Value)
      • 5.2.1. Global Chemotherapy by: Type (Value)
        • 5.2.1.1. Alkylating Agents
        • 5.2.1.2. Anti-metabolites
        • 5.2.1.3. Plant Alkaloids and Terpenoids
        • 5.2.1.4. Podophyllotoxin
        • 5.2.1.5. Taxanes
        • 5.2.1.6. Topoisomerase Inhibitor
        • 5.2.1.7. Anti-Tumour Antibiotics
        • 5.2.1.8. Hormones
        • 5.2.1.9. Monoclonal Antibodies
        • 5.2.1.10. Others
      • 5.2.2. Global Chemotherapy by: Route of Administration (Value)
        • 5.2.2.1. Intravenous
        • 5.2.2.2. Oral
        • 5.2.2.3. Subcutaneous
        • 5.2.2.4. Intra-Muscular
        • 5.2.2.5. Intravesicular
        • 5.2.2.6. Topical
        • 5.2.2.7. Intraperitoneal
        • 5.2.2.8. Intraventricular/Intrathecal
      • 5.2.3. Global Chemotherapy by: Indication (Value)
        • 5.2.3.1. Oncology/Cancer
        • 5.2.3.2. Bone Marrow Diseases
        • 5.2.3.3. Immune System Disorders
        • 5.2.3.4. Others
      • 5.2.4. Global Chemotherapy by: Distribution Channel (Value)
        • 5.2.4.1. Hospital Pharmacy
        • 5.2.4.2. Retail Pharmacy
        • 5.2.4.3. Online Pharmacy
        • 5.2.4.4. Others
      • 5.2.5. Global Chemotherapy by: Dosage Form (Value)
        • 5.2.5.1. Capsule
        • 5.2.5.2. Tablets
        • 5.2.5.3. Injections
        • 5.2.5.4. Others
      • 5.2.6. Global Chemotherapy by: Drug Class (Value)
        • 5.2.6.1. Alkylating Agents
        • 5.2.6.2. Mitotic Inhibitors
        • 5.2.6.3. Antimetabolites
        • 5.2.6.4. Topoisomerase Inhibitors
        • 5.2.6.5. Antitumor Antibiotic
      • 5.2.7. Global Chemotherapy Region
        • 5.2.7.1. South America
          • 5.2.7.1.1. Brazil
          • 5.2.7.1.2. Argentina
          • 5.2.7.1.3. Rest of South America
        • 5.2.7.2. Asia Pacific
          • 5.2.7.2.1. China
          • 5.2.7.2.2. Japan
          • 5.2.7.2.3. India
          • 5.2.7.2.4. South Korea
          • 5.2.7.2.5. Taiwan
          • 5.2.7.2.6. Australia
          • 5.2.7.2.7. Rest of Asia-Pacific
        • 5.2.7.3. Europe
          • 5.2.7.3.1. Germany
          • 5.2.7.3.2. France
          • 5.2.7.3.3. Italy
          • 5.2.7.3.4. United Kingdom
          • 5.2.7.3.5. Netherlands
          • 5.2.7.3.6. Rest of Europe
        • 5.2.7.4. MEA
          • 5.2.7.4.1. Middle East
          • 5.2.7.4.2. Africa
        • 5.2.7.5. North America
          • 5.2.7.5.1. United States
          • 5.2.7.5.2. Canada
          • 5.2.7.5.3. Mexico
  • 6. Chemotherapy: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2023)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Novartis AG (Switzerland)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Pfizer Inc. (United States)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Johnson & Johnson Services Inc. (United States)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Bristol-Myers Squibb Company (United States)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. GlaxoSmithKline PLC (United Kingdom)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Eli Lilly and Company (United States)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. F. Hoffmann-La Roche Ltd (Switzerland)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Merck & Co. Inc. (United States)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Sanofi S.A. (France)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Celgene Corporation (United States)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
  • 7. Global Chemotherapy Sale, by Type, Route of Administration, Indication, Distribution Channel, Dosage Form, Drug Class and Region (value) (2025-2030)
    • 7.1. Introduction
    • 7.2. Global Chemotherapy (Value)
      • 7.2.1. Global Chemotherapy by: Type (Value)
        • 7.2.1.1. Alkylating Agents
        • 7.2.1.2. Anti-metabolites
        • 7.2.1.3. Plant Alkaloids and Terpenoids
        • 7.2.1.4. Podophyllotoxin
        • 7.2.1.5. Taxanes
        • 7.2.1.6. Topoisomerase Inhibitor
        • 7.2.1.7. Anti-Tumour Antibiotics
        • 7.2.1.8. Hormones
        • 7.2.1.9. Monoclonal Antibodies
        • 7.2.1.10. Others
      • 7.2.2. Global Chemotherapy by: Route of Administration (Value)
        • 7.2.2.1. Intravenous
        • 7.2.2.2. Oral
        • 7.2.2.3. Subcutaneous
        • 7.2.2.4. Intra-Muscular
        • 7.2.2.5. Intravesicular
        • 7.2.2.6. Topical
        • 7.2.2.7. Intraperitoneal
        • 7.2.2.8. Intraventricular/Intrathecal
      • 7.2.3. Global Chemotherapy by: Indication (Value)
        • 7.2.3.1. Oncology/Cancer
        • 7.2.3.2. Bone Marrow Diseases
        • 7.2.3.3. Immune System Disorders
        • 7.2.3.4. Others
      • 7.2.4. Global Chemotherapy by: Distribution Channel (Value)
        • 7.2.4.1. Hospital Pharmacy
        • 7.2.4.2. Retail Pharmacy
        • 7.2.4.3. Online Pharmacy
        • 7.2.4.4. Others
      • 7.2.5. Global Chemotherapy by: Dosage Form (Value)
        • 7.2.5.1. Capsule
        • 7.2.5.2. Tablets
        • 7.2.5.3. Injections
        • 7.2.5.4. Others
      • 7.2.6. Global Chemotherapy by: Drug Class (Value)
        • 7.2.6.1. Alkylating Agents
        • 7.2.6.2. Mitotic Inhibitors
        • 7.2.6.3. Antimetabolites
        • 7.2.6.4. Topoisomerase Inhibitors
        • 7.2.6.5. Antitumor Antibiotic
      • 7.2.7. Global Chemotherapy Region
        • 7.2.7.1. South America
          • 7.2.7.1.1. Brazil
          • 7.2.7.1.2. Argentina
          • 7.2.7.1.3. Rest of South America
        • 7.2.7.2. Asia Pacific
          • 7.2.7.2.1. China
          • 7.2.7.2.2. Japan
          • 7.2.7.2.3. India
          • 7.2.7.2.4. South Korea
          • 7.2.7.2.5. Taiwan
          • 7.2.7.2.6. Australia
          • 7.2.7.2.7. Rest of Asia-Pacific
        • 7.2.7.3. Europe
          • 7.2.7.3.1. Germany
          • 7.2.7.3.2. France
          • 7.2.7.3.3. Italy
          • 7.2.7.3.4. United Kingdom
          • 7.2.7.3.5. Netherlands
          • 7.2.7.3.6. Rest of Europe
        • 7.2.7.4. MEA
          • 7.2.7.4.1. Middle East
          • 7.2.7.4.2. Africa
        • 7.2.7.5. North America
          • 7.2.7.5.1. United States
          • 7.2.7.5.2. Canada
          • 7.2.7.5.3. Mexico
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Chemotherapy: by Type(USD Million)
  • Table 2. Chemotherapy Alkylating Agents , by Region USD Million (2018-2023)
  • Table 3. Chemotherapy Anti-metabolites , by Region USD Million (2018-2023)
  • Table 4. Chemotherapy Plant Alkaloids and Terpenoids , by Region USD Million (2018-2023)
  • Table 5. Chemotherapy Podophyllotoxin , by Region USD Million (2018-2023)
  • Table 6. Chemotherapy Taxanes , by Region USD Million (2018-2023)
  • Table 7. Chemotherapy Topoisomerase Inhibitor , by Region USD Million (2018-2023)
  • Table 8. Chemotherapy Anti-Tumour Antibiotics , by Region USD Million (2018-2023)
  • Table 9. Chemotherapy Hormones , by Region USD Million (2018-2023)
  • Table 10. Chemotherapy Monoclonal Antibodies , by Region USD Million (2018-2023)
  • Table 11. Chemotherapy Others , by Region USD Million (2018-2023)
  • Table 12. Chemotherapy: by Route of Administration(USD Million)
  • Table 13. Chemotherapy Intravenous , by Region USD Million (2018-2023)
  • Table 14. Chemotherapy Oral , by Region USD Million (2018-2023)
  • Table 15. Chemotherapy Subcutaneous , by Region USD Million (2018-2023)
  • Table 16. Chemotherapy Intra-Muscular , by Region USD Million (2018-2023)
  • Table 17. Chemotherapy Intravesicular , by Region USD Million (2018-2023)
  • Table 18. Chemotherapy Topical , by Region USD Million (2018-2023)
  • Table 19. Chemotherapy Intraperitoneal , by Region USD Million (2018-2023)
  • Table 20. Chemotherapy Intraventricular/Intrathecal , by Region USD Million (2018-2023)
  • Table 21. Chemotherapy: by Indication(USD Million)
  • Table 22. Chemotherapy Oncology/Cancer , by Region USD Million (2018-2023)
  • Table 23. Chemotherapy Bone Marrow Diseases , by Region USD Million (2018-2023)
  • Table 24. Chemotherapy Immune System Disorders , by Region USD Million (2018-2023)
  • Table 25. Chemotherapy Others , by Region USD Million (2018-2023)
  • Table 26. Chemotherapy: by Distribution Channel(USD Million)
  • Table 27. Chemotherapy Hospital Pharmacy , by Region USD Million (2018-2023)
  • Table 28. Chemotherapy Retail Pharmacy , by Region USD Million (2018-2023)
  • Table 29. Chemotherapy Online Pharmacy , by Region USD Million (2018-2023)
  • Table 30. Chemotherapy Others , by Region USD Million (2018-2023)
  • Table 31. Chemotherapy: by Dosage Form(USD Million)
  • Table 32. Chemotherapy Capsule , by Region USD Million (2018-2023)
  • Table 33. Chemotherapy Tablets , by Region USD Million (2018-2023)
  • Table 34. Chemotherapy Injections , by Region USD Million (2018-2023)
  • Table 35. Chemotherapy Others , by Region USD Million (2018-2023)
  • Table 36. Chemotherapy: by Drug Class(USD Million)
  • Table 37. Chemotherapy Alkylating Agents , by Region USD Million (2018-2023)
  • Table 38. Chemotherapy Mitotic Inhibitors , by Region USD Million (2018-2023)
  • Table 39. Chemotherapy Antimetabolites , by Region USD Million (2018-2023)
  • Table 40. Chemotherapy Topoisomerase Inhibitors , by Region USD Million (2018-2023)
  • Table 41. Chemotherapy Antitumor Antibiotic , by Region USD Million (2018-2023)
  • Table 42. South America Chemotherapy, by Country USD Million (2018-2023)
  • Table 43. South America Chemotherapy, by Type USD Million (2018-2023)
  • Table 44. South America Chemotherapy, by Route of Administration USD Million (2018-2023)
  • Table 45. South America Chemotherapy, by Indication USD Million (2018-2023)
  • Table 46. South America Chemotherapy, by Distribution Channel USD Million (2018-2023)
  • Table 47. South America Chemotherapy, by Dosage Form USD Million (2018-2023)
  • Table 48. South America Chemotherapy, by Drug Class USD Million (2018-2023)
  • Table 49. Brazil Chemotherapy, by Type USD Million (2018-2023)
  • Table 50. Brazil Chemotherapy, by Route of Administration USD Million (2018-2023)
  • Table 51. Brazil Chemotherapy, by Indication USD Million (2018-2023)
  • Table 52. Brazil Chemotherapy, by Distribution Channel USD Million (2018-2023)
  • Table 53. Brazil Chemotherapy, by Dosage Form USD Million (2018-2023)
  • Table 54. Brazil Chemotherapy, by Drug Class USD Million (2018-2023)
  • Table 55. Argentina Chemotherapy, by Type USD Million (2018-2023)
  • Table 56. Argentina Chemotherapy, by Route of Administration USD Million (2018-2023)
  • Table 57. Argentina Chemotherapy, by Indication USD Million (2018-2023)
  • Table 58. Argentina Chemotherapy, by Distribution Channel USD Million (2018-2023)
  • Table 59. Argentina Chemotherapy, by Dosage Form USD Million (2018-2023)
  • Table 60. Argentina Chemotherapy, by Drug Class USD Million (2018-2023)
  • Table 61. Rest of South America Chemotherapy, by Type USD Million (2018-2023)
  • Table 62. Rest of South America Chemotherapy, by Route of Administration USD Million (2018-2023)
  • Table 63. Rest of South America Chemotherapy, by Indication USD Million (2018-2023)
  • Table 64. Rest of South America Chemotherapy, by Distribution Channel USD Million (2018-2023)
  • Table 65. Rest of South America Chemotherapy, by Dosage Form USD Million (2018-2023)
  • Table 66. Rest of South America Chemotherapy, by Drug Class USD Million (2018-2023)
  • Table 67. Asia Pacific Chemotherapy, by Country USD Million (2018-2023)
  • Table 68. Asia Pacific Chemotherapy, by Type USD Million (2018-2023)
  • Table 69. Asia Pacific Chemotherapy, by Route of Administration USD Million (2018-2023)
  • Table 70. Asia Pacific Chemotherapy, by Indication USD Million (2018-2023)
  • Table 71. Asia Pacific Chemotherapy, by Distribution Channel USD Million (2018-2023)
  • Table 72. Asia Pacific Chemotherapy, by Dosage Form USD Million (2018-2023)
  • Table 73. Asia Pacific Chemotherapy, by Drug Class USD Million (2018-2023)
  • Table 74. China Chemotherapy, by Type USD Million (2018-2023)
  • Table 75. China Chemotherapy, by Route of Administration USD Million (2018-2023)
  • Table 76. China Chemotherapy, by Indication USD Million (2018-2023)
  • Table 77. China Chemotherapy, by Distribution Channel USD Million (2018-2023)
  • Table 78. China Chemotherapy, by Dosage Form USD Million (2018-2023)
  • Table 79. China Chemotherapy, by Drug Class USD Million (2018-2023)
  • Table 80. Japan Chemotherapy, by Type USD Million (2018-2023)
  • Table 81. Japan Chemotherapy, by Route of Administration USD Million (2018-2023)
  • Table 82. Japan Chemotherapy, by Indication USD Million (2018-2023)
  • Table 83. Japan Chemotherapy, by Distribution Channel USD Million (2018-2023)
  • Table 84. Japan Chemotherapy, by Dosage Form USD Million (2018-2023)
  • Table 85. Japan Chemotherapy, by Drug Class USD Million (2018-2023)
  • Table 86. India Chemotherapy, by Type USD Million (2018-2023)
  • Table 87. India Chemotherapy, by Route of Administration USD Million (2018-2023)
  • Table 88. India Chemotherapy, by Indication USD Million (2018-2023)
  • Table 89. India Chemotherapy, by Distribution Channel USD Million (2018-2023)
  • Table 90. India Chemotherapy, by Dosage Form USD Million (2018-2023)
  • Table 91. India Chemotherapy, by Drug Class USD Million (2018-2023)
  • Table 92. South Korea Chemotherapy, by Type USD Million (2018-2023)
  • Table 93. South Korea Chemotherapy, by Route of Administration USD Million (2018-2023)
  • Table 94. South Korea Chemotherapy, by Indication USD Million (2018-2023)
  • Table 95. South Korea Chemotherapy, by Distribution Channel USD Million (2018-2023)
  • Table 96. South Korea Chemotherapy, by Dosage Form USD Million (2018-2023)
  • Table 97. South Korea Chemotherapy, by Drug Class USD Million (2018-2023)
  • Table 98. Taiwan Chemotherapy, by Type USD Million (2018-2023)
  • Table 99. Taiwan Chemotherapy, by Route of Administration USD Million (2018-2023)
  • Table 100. Taiwan Chemotherapy, by Indication USD Million (2018-2023)
  • Table 101. Taiwan Chemotherapy, by Distribution Channel USD Million (2018-2023)
  • Table 102. Taiwan Chemotherapy, by Dosage Form USD Million (2018-2023)
  • Table 103. Taiwan Chemotherapy, by Drug Class USD Million (2018-2023)
  • Table 104. Australia Chemotherapy, by Type USD Million (2018-2023)
  • Table 105. Australia Chemotherapy, by Route of Administration USD Million (2018-2023)
  • Table 106. Australia Chemotherapy, by Indication USD Million (2018-2023)
  • Table 107. Australia Chemotherapy, by Distribution Channel USD Million (2018-2023)
  • Table 108. Australia Chemotherapy, by Dosage Form USD Million (2018-2023)
  • Table 109. Australia Chemotherapy, by Drug Class USD Million (2018-2023)
  • Table 110. Rest of Asia-Pacific Chemotherapy, by Type USD Million (2018-2023)
  • Table 111. Rest of Asia-Pacific Chemotherapy, by Route of Administration USD Million (2018-2023)
  • Table 112. Rest of Asia-Pacific Chemotherapy, by Indication USD Million (2018-2023)
  • Table 113. Rest of Asia-Pacific Chemotherapy, by Distribution Channel USD Million (2018-2023)
  • Table 114. Rest of Asia-Pacific Chemotherapy, by Dosage Form USD Million (2018-2023)
  • Table 115. Rest of Asia-Pacific Chemotherapy, by Drug Class USD Million (2018-2023)
  • Table 116. Europe Chemotherapy, by Country USD Million (2018-2023)
  • Table 117. Europe Chemotherapy, by Type USD Million (2018-2023)
  • Table 118. Europe Chemotherapy, by Route of Administration USD Million (2018-2023)
  • Table 119. Europe Chemotherapy, by Indication USD Million (2018-2023)
  • Table 120. Europe Chemotherapy, by Distribution Channel USD Million (2018-2023)
  • Table 121. Europe Chemotherapy, by Dosage Form USD Million (2018-2023)
  • Table 122. Europe Chemotherapy, by Drug Class USD Million (2018-2023)
  • Table 123. Germany Chemotherapy, by Type USD Million (2018-2023)
  • Table 124. Germany Chemotherapy, by Route of Administration USD Million (2018-2023)
  • Table 125. Germany Chemotherapy, by Indication USD Million (2018-2023)
  • Table 126. Germany Chemotherapy, by Distribution Channel USD Million (2018-2023)
  • Table 127. Germany Chemotherapy, by Dosage Form USD Million (2018-2023)
  • Table 128. Germany Chemotherapy, by Drug Class USD Million (2018-2023)
  • Table 129. France Chemotherapy, by Type USD Million (2018-2023)
  • Table 130. France Chemotherapy, by Route of Administration USD Million (2018-2023)
  • Table 131. France Chemotherapy, by Indication USD Million (2018-2023)
  • Table 132. France Chemotherapy, by Distribution Channel USD Million (2018-2023)
  • Table 133. France Chemotherapy, by Dosage Form USD Million (2018-2023)
  • Table 134. France Chemotherapy, by Drug Class USD Million (2018-2023)
  • Table 135. Italy Chemotherapy, by Type USD Million (2018-2023)
  • Table 136. Italy Chemotherapy, by Route of Administration USD Million (2018-2023)
  • Table 137. Italy Chemotherapy, by Indication USD Million (2018-2023)
  • Table 138. Italy Chemotherapy, by Distribution Channel USD Million (2018-2023)
  • Table 139. Italy Chemotherapy, by Dosage Form USD Million (2018-2023)
  • Table 140. Italy Chemotherapy, by Drug Class USD Million (2018-2023)
  • Table 141. United Kingdom Chemotherapy, by Type USD Million (2018-2023)
  • Table 142. United Kingdom Chemotherapy, by Route of Administration USD Million (2018-2023)
  • Table 143. United Kingdom Chemotherapy, by Indication USD Million (2018-2023)
  • Table 144. United Kingdom Chemotherapy, by Distribution Channel USD Million (2018-2023)
  • Table 145. United Kingdom Chemotherapy, by Dosage Form USD Million (2018-2023)
  • Table 146. United Kingdom Chemotherapy, by Drug Class USD Million (2018-2023)
  • Table 147. Netherlands Chemotherapy, by Type USD Million (2018-2023)
  • Table 148. Netherlands Chemotherapy, by Route of Administration USD Million (2018-2023)
  • Table 149. Netherlands Chemotherapy, by Indication USD Million (2018-2023)
  • Table 150. Netherlands Chemotherapy, by Distribution Channel USD Million (2018-2023)
  • Table 151. Netherlands Chemotherapy, by Dosage Form USD Million (2018-2023)
  • Table 152. Netherlands Chemotherapy, by Drug Class USD Million (2018-2023)
  • Table 153. Rest of Europe Chemotherapy, by Type USD Million (2018-2023)
  • Table 154. Rest of Europe Chemotherapy, by Route of Administration USD Million (2018-2023)
  • Table 155. Rest of Europe Chemotherapy, by Indication USD Million (2018-2023)
  • Table 156. Rest of Europe Chemotherapy, by Distribution Channel USD Million (2018-2023)
  • Table 157. Rest of Europe Chemotherapy, by Dosage Form USD Million (2018-2023)
  • Table 158. Rest of Europe Chemotherapy, by Drug Class USD Million (2018-2023)
  • Table 159. MEA Chemotherapy, by Country USD Million (2018-2023)
  • Table 160. MEA Chemotherapy, by Type USD Million (2018-2023)
  • Table 161. MEA Chemotherapy, by Route of Administration USD Million (2018-2023)
  • Table 162. MEA Chemotherapy, by Indication USD Million (2018-2023)
  • Table 163. MEA Chemotherapy, by Distribution Channel USD Million (2018-2023)
  • Table 164. MEA Chemotherapy, by Dosage Form USD Million (2018-2023)
  • Table 165. MEA Chemotherapy, by Drug Class USD Million (2018-2023)
  • Table 166. Middle East Chemotherapy, by Type USD Million (2018-2023)
  • Table 167. Middle East Chemotherapy, by Route of Administration USD Million (2018-2023)
  • Table 168. Middle East Chemotherapy, by Indication USD Million (2018-2023)
  • Table 169. Middle East Chemotherapy, by Distribution Channel USD Million (2018-2023)
  • Table 170. Middle East Chemotherapy, by Dosage Form USD Million (2018-2023)
  • Table 171. Middle East Chemotherapy, by Drug Class USD Million (2018-2023)
  • Table 172. Africa Chemotherapy, by Type USD Million (2018-2023)
  • Table 173. Africa Chemotherapy, by Route of Administration USD Million (2018-2023)
  • Table 174. Africa Chemotherapy, by Indication USD Million (2018-2023)
  • Table 175. Africa Chemotherapy, by Distribution Channel USD Million (2018-2023)
  • Table 176. Africa Chemotherapy, by Dosage Form USD Million (2018-2023)
  • Table 177. Africa Chemotherapy, by Drug Class USD Million (2018-2023)
  • Table 178. North America Chemotherapy, by Country USD Million (2018-2023)
  • Table 179. North America Chemotherapy, by Type USD Million (2018-2023)
  • Table 180. North America Chemotherapy, by Route of Administration USD Million (2018-2023)
  • Table 181. North America Chemotherapy, by Indication USD Million (2018-2023)
  • Table 182. North America Chemotherapy, by Distribution Channel USD Million (2018-2023)
  • Table 183. North America Chemotherapy, by Dosage Form USD Million (2018-2023)
  • Table 184. North America Chemotherapy, by Drug Class USD Million (2018-2023)
  • Table 185. United States Chemotherapy, by Type USD Million (2018-2023)
  • Table 186. United States Chemotherapy, by Route of Administration USD Million (2018-2023)
  • Table 187. United States Chemotherapy, by Indication USD Million (2018-2023)
  • Table 188. United States Chemotherapy, by Distribution Channel USD Million (2018-2023)
  • Table 189. United States Chemotherapy, by Dosage Form USD Million (2018-2023)
  • Table 190. United States Chemotherapy, by Drug Class USD Million (2018-2023)
  • Table 191. Canada Chemotherapy, by Type USD Million (2018-2023)
  • Table 192. Canada Chemotherapy, by Route of Administration USD Million (2018-2023)
  • Table 193. Canada Chemotherapy, by Indication USD Million (2018-2023)
  • Table 194. Canada Chemotherapy, by Distribution Channel USD Million (2018-2023)
  • Table 195. Canada Chemotherapy, by Dosage Form USD Million (2018-2023)
  • Table 196. Canada Chemotherapy, by Drug Class USD Million (2018-2023)
  • Table 197. Mexico Chemotherapy, by Type USD Million (2018-2023)
  • Table 198. Mexico Chemotherapy, by Route of Administration USD Million (2018-2023)
  • Table 199. Mexico Chemotherapy, by Indication USD Million (2018-2023)
  • Table 200. Mexico Chemotherapy, by Distribution Channel USD Million (2018-2023)
  • Table 201. Mexico Chemotherapy, by Dosage Form USD Million (2018-2023)
  • Table 202. Mexico Chemotherapy, by Drug Class USD Million (2018-2023)
  • Table 203. Company Basic Information, Sales Area and Its Competitors
  • Table 204. Company Basic Information, Sales Area and Its Competitors
  • Table 205. Company Basic Information, Sales Area and Its Competitors
  • Table 206. Company Basic Information, Sales Area and Its Competitors
  • Table 207. Company Basic Information, Sales Area and Its Competitors
  • Table 208. Company Basic Information, Sales Area and Its Competitors
  • Table 209. Company Basic Information, Sales Area and Its Competitors
  • Table 210. Company Basic Information, Sales Area and Its Competitors
  • Table 211. Company Basic Information, Sales Area and Its Competitors
  • Table 212. Company Basic Information, Sales Area and Its Competitors
  • Table 213. Chemotherapy: by Type(USD Million)
  • Table 214. Chemotherapy Alkylating Agents , by Region USD Million (2025-2030)
  • Table 215. Chemotherapy Anti-metabolites , by Region USD Million (2025-2030)
  • Table 216. Chemotherapy Plant Alkaloids and Terpenoids , by Region USD Million (2025-2030)
  • Table 217. Chemotherapy Podophyllotoxin , by Region USD Million (2025-2030)
  • Table 218. Chemotherapy Taxanes , by Region USD Million (2025-2030)
  • Table 219. Chemotherapy Topoisomerase Inhibitor , by Region USD Million (2025-2030)
  • Table 220. Chemotherapy Anti-Tumour Antibiotics , by Region USD Million (2025-2030)
  • Table 221. Chemotherapy Hormones , by Region USD Million (2025-2030)
  • Table 222. Chemotherapy Monoclonal Antibodies , by Region USD Million (2025-2030)
  • Table 223. Chemotherapy Others , by Region USD Million (2025-2030)
  • Table 224. Chemotherapy: by Route of Administration(USD Million)
  • Table 225. Chemotherapy Intravenous , by Region USD Million (2025-2030)
  • Table 226. Chemotherapy Oral , by Region USD Million (2025-2030)
  • Table 227. Chemotherapy Subcutaneous , by Region USD Million (2025-2030)
  • Table 228. Chemotherapy Intra-Muscular , by Region USD Million (2025-2030)
  • Table 229. Chemotherapy Intravesicular , by Region USD Million (2025-2030)
  • Table 230. Chemotherapy Topical , by Region USD Million (2025-2030)
  • Table 231. Chemotherapy Intraperitoneal , by Region USD Million (2025-2030)
  • Table 232. Chemotherapy Intraventricular/Intrathecal , by Region USD Million (2025-2030)
  • Table 233. Chemotherapy: by Indication(USD Million)
  • Table 234. Chemotherapy Oncology/Cancer , by Region USD Million (2025-2030)
  • Table 235. Chemotherapy Bone Marrow Diseases , by Region USD Million (2025-2030)
  • Table 236. Chemotherapy Immune System Disorders , by Region USD Million (2025-2030)
  • Table 237. Chemotherapy Others , by Region USD Million (2025-2030)
  • Table 238. Chemotherapy: by Distribution Channel(USD Million)
  • Table 239. Chemotherapy Hospital Pharmacy , by Region USD Million (2025-2030)
  • Table 240. Chemotherapy Retail Pharmacy , by Region USD Million (2025-2030)
  • Table 241. Chemotherapy Online Pharmacy , by Region USD Million (2025-2030)
  • Table 242. Chemotherapy Others , by Region USD Million (2025-2030)
  • Table 243. Chemotherapy: by Dosage Form(USD Million)
  • Table 244. Chemotherapy Capsule , by Region USD Million (2025-2030)
  • Table 245. Chemotherapy Tablets , by Region USD Million (2025-2030)
  • Table 246. Chemotherapy Injections , by Region USD Million (2025-2030)
  • Table 247. Chemotherapy Others , by Region USD Million (2025-2030)
  • Table 248. Chemotherapy: by Drug Class(USD Million)
  • Table 249. Chemotherapy Alkylating Agents , by Region USD Million (2025-2030)
  • Table 250. Chemotherapy Mitotic Inhibitors , by Region USD Million (2025-2030)
  • Table 251. Chemotherapy Antimetabolites , by Region USD Million (2025-2030)
  • Table 252. Chemotherapy Topoisomerase Inhibitors , by Region USD Million (2025-2030)
  • Table 253. Chemotherapy Antitumor Antibiotic , by Region USD Million (2025-2030)
  • Table 254. South America Chemotherapy, by Country USD Million (2025-2030)
  • Table 255. South America Chemotherapy, by Type USD Million (2025-2030)
  • Table 256. South America Chemotherapy, by Route of Administration USD Million (2025-2030)
  • Table 257. South America Chemotherapy, by Indication USD Million (2025-2030)
  • Table 258. South America Chemotherapy, by Distribution Channel USD Million (2025-2030)
  • Table 259. South America Chemotherapy, by Dosage Form USD Million (2025-2030)
  • Table 260. South America Chemotherapy, by Drug Class USD Million (2025-2030)
  • Table 261. Brazil Chemotherapy, by Type USD Million (2025-2030)
  • Table 262. Brazil Chemotherapy, by Route of Administration USD Million (2025-2030)
  • Table 263. Brazil Chemotherapy, by Indication USD Million (2025-2030)
  • Table 264. Brazil Chemotherapy, by Distribution Channel USD Million (2025-2030)
  • Table 265. Brazil Chemotherapy, by Dosage Form USD Million (2025-2030)
  • Table 266. Brazil Chemotherapy, by Drug Class USD Million (2025-2030)
  • Table 267. Argentina Chemotherapy, by Type USD Million (2025-2030)
  • Table 268. Argentina Chemotherapy, by Route of Administration USD Million (2025-2030)
  • Table 269. Argentina Chemotherapy, by Indication USD Million (2025-2030)
  • Table 270. Argentina Chemotherapy, by Distribution Channel USD Million (2025-2030)
  • Table 271. Argentina Chemotherapy, by Dosage Form USD Million (2025-2030)
  • Table 272. Argentina Chemotherapy, by Drug Class USD Million (2025-2030)
  • Table 273. Rest of South America Chemotherapy, by Type USD Million (2025-2030)
  • Table 274. Rest of South America Chemotherapy, by Route of Administration USD Million (2025-2030)
  • Table 275. Rest of South America Chemotherapy, by Indication USD Million (2025-2030)
  • Table 276. Rest of South America Chemotherapy, by Distribution Channel USD Million (2025-2030)
  • Table 277. Rest of South America Chemotherapy, by Dosage Form USD Million (2025-2030)
  • Table 278. Rest of South America Chemotherapy, by Drug Class USD Million (2025-2030)
  • Table 279. Asia Pacific Chemotherapy, by Country USD Million (2025-2030)
  • Table 280. Asia Pacific Chemotherapy, by Type USD Million (2025-2030)
  • Table 281. Asia Pacific Chemotherapy, by Route of Administration USD Million (2025-2030)
  • Table 282. Asia Pacific Chemotherapy, by Indication USD Million (2025-2030)
  • Table 283. Asia Pacific Chemotherapy, by Distribution Channel USD Million (2025-2030)
  • Table 284. Asia Pacific Chemotherapy, by Dosage Form USD Million (2025-2030)
  • Table 285. Asia Pacific Chemotherapy, by Drug Class USD Million (2025-2030)
  • Table 286. China Chemotherapy, by Type USD Million (2025-2030)
  • Table 287. China Chemotherapy, by Route of Administration USD Million (2025-2030)
  • Table 288. China Chemotherapy, by Indication USD Million (2025-2030)
  • Table 289. China Chemotherapy, by Distribution Channel USD Million (2025-2030)
  • Table 290. China Chemotherapy, by Dosage Form USD Million (2025-2030)
  • Table 291. China Chemotherapy, by Drug Class USD Million (2025-2030)
  • Table 292. Japan Chemotherapy, by Type USD Million (2025-2030)
  • Table 293. Japan Chemotherapy, by Route of Administration USD Million (2025-2030)
  • Table 294. Japan Chemotherapy, by Indication USD Million (2025-2030)
  • Table 295. Japan Chemotherapy, by Distribution Channel USD Million (2025-2030)
  • Table 296. Japan Chemotherapy, by Dosage Form USD Million (2025-2030)
  • Table 297. Japan Chemotherapy, by Drug Class USD Million (2025-2030)
  • Table 298. India Chemotherapy, by Type USD Million (2025-2030)
  • Table 299. India Chemotherapy, by Route of Administration USD Million (2025-2030)
  • Table 300. India Chemotherapy, by Indication USD Million (2025-2030)
  • Table 301. India Chemotherapy, by Distribution Channel USD Million (2025-2030)
  • Table 302. India Chemotherapy, by Dosage Form USD Million (2025-2030)
  • Table 303. India Chemotherapy, by Drug Class USD Million (2025-2030)
  • Table 304. South Korea Chemotherapy, by Type USD Million (2025-2030)
  • Table 305. South Korea Chemotherapy, by Route of Administration USD Million (2025-2030)
  • Table 306. South Korea Chemotherapy, by Indication USD Million (2025-2030)
  • Table 307. South Korea Chemotherapy, by Distribution Channel USD Million (2025-2030)
  • Table 308. South Korea Chemotherapy, by Dosage Form USD Million (2025-2030)
  • Table 309. South Korea Chemotherapy, by Drug Class USD Million (2025-2030)
  • Table 310. Taiwan Chemotherapy, by Type USD Million (2025-2030)
  • Table 311. Taiwan Chemotherapy, by Route of Administration USD Million (2025-2030)
  • Table 312. Taiwan Chemotherapy, by Indication USD Million (2025-2030)
  • Table 313. Taiwan Chemotherapy, by Distribution Channel USD Million (2025-2030)
  • Table 314. Taiwan Chemotherapy, by Dosage Form USD Million (2025-2030)
  • Table 315. Taiwan Chemotherapy, by Drug Class USD Million (2025-2030)
  • Table 316. Australia Chemotherapy, by Type USD Million (2025-2030)
  • Table 317. Australia Chemotherapy, by Route of Administration USD Million (2025-2030)
  • Table 318. Australia Chemotherapy, by Indication USD Million (2025-2030)
  • Table 319. Australia Chemotherapy, by Distribution Channel USD Million (2025-2030)
  • Table 320. Australia Chemotherapy, by Dosage Form USD Million (2025-2030)
  • Table 321. Australia Chemotherapy, by Drug Class USD Million (2025-2030)
  • Table 322. Rest of Asia-Pacific Chemotherapy, by Type USD Million (2025-2030)
  • Table 323. Rest of Asia-Pacific Chemotherapy, by Route of Administration USD Million (2025-2030)
  • Table 324. Rest of Asia-Pacific Chemotherapy, by Indication USD Million (2025-2030)
  • Table 325. Rest of Asia-Pacific Chemotherapy, by Distribution Channel USD Million (2025-2030)
  • Table 326. Rest of Asia-Pacific Chemotherapy, by Dosage Form USD Million (2025-2030)
  • Table 327. Rest of Asia-Pacific Chemotherapy, by Drug Class USD Million (2025-2030)
  • Table 328. Europe Chemotherapy, by Country USD Million (2025-2030)
  • Table 329. Europe Chemotherapy, by Type USD Million (2025-2030)
  • Table 330. Europe Chemotherapy, by Route of Administration USD Million (2025-2030)
  • Table 331. Europe Chemotherapy, by Indication USD Million (2025-2030)
  • Table 332. Europe Chemotherapy, by Distribution Channel USD Million (2025-2030)
  • Table 333. Europe Chemotherapy, by Dosage Form USD Million (2025-2030)
  • Table 334. Europe Chemotherapy, by Drug Class USD Million (2025-2030)
  • Table 335. Germany Chemotherapy, by Type USD Million (2025-2030)
  • Table 336. Germany Chemotherapy, by Route of Administration USD Million (2025-2030)
  • Table 337. Germany Chemotherapy, by Indication USD Million (2025-2030)
  • Table 338. Germany Chemotherapy, by Distribution Channel USD Million (2025-2030)
  • Table 339. Germany Chemotherapy, by Dosage Form USD Million (2025-2030)
  • Table 340. Germany Chemotherapy, by Drug Class USD Million (2025-2030)
  • Table 341. France Chemotherapy, by Type USD Million (2025-2030)
  • Table 342. France Chemotherapy, by Route of Administration USD Million (2025-2030)
  • Table 343. France Chemotherapy, by Indication USD Million (2025-2030)
  • Table 344. France Chemotherapy, by Distribution Channel USD Million (2025-2030)
  • Table 345. France Chemotherapy, by Dosage Form USD Million (2025-2030)
  • Table 346. France Chemotherapy, by Drug Class USD Million (2025-2030)
  • Table 347. Italy Chemotherapy, by Type USD Million (2025-2030)
  • Table 348. Italy Chemotherapy, by Route of Administration USD Million (2025-2030)
  • Table 349. Italy Chemotherapy, by Indication USD Million (2025-2030)
  • Table 350. Italy Chemotherapy, by Distribution Channel USD Million (2025-2030)
  • Table 351. Italy Chemotherapy, by Dosage Form USD Million (2025-2030)
  • Table 352. Italy Chemotherapy, by Drug Class USD Million (2025-2030)
  • Table 353. United Kingdom Chemotherapy, by Type USD Million (2025-2030)
  • Table 354. United Kingdom Chemotherapy, by Route of Administration USD Million (2025-2030)
  • Table 355. United Kingdom Chemotherapy, by Indication USD Million (2025-2030)
  • Table 356. United Kingdom Chemotherapy, by Distribution Channel USD Million (2025-2030)
  • Table 357. United Kingdom Chemotherapy, by Dosage Form USD Million (2025-2030)
  • Table 358. United Kingdom Chemotherapy, by Drug Class USD Million (2025-2030)
  • Table 359. Netherlands Chemotherapy, by Type USD Million (2025-2030)
  • Table 360. Netherlands Chemotherapy, by Route of Administration USD Million (2025-2030)
  • Table 361. Netherlands Chemotherapy, by Indication USD Million (2025-2030)
  • Table 362. Netherlands Chemotherapy, by Distribution Channel USD Million (2025-2030)
  • Table 363. Netherlands Chemotherapy, by Dosage Form USD Million (2025-2030)
  • Table 364. Netherlands Chemotherapy, by Drug Class USD Million (2025-2030)
  • Table 365. Rest of Europe Chemotherapy, by Type USD Million (2025-2030)
  • Table 366. Rest of Europe Chemotherapy, by Route of Administration USD Million (2025-2030)
  • Table 367. Rest of Europe Chemotherapy, by Indication USD Million (2025-2030)
  • Table 368. Rest of Europe Chemotherapy, by Distribution Channel USD Million (2025-2030)
  • Table 369. Rest of Europe Chemotherapy, by Dosage Form USD Million (2025-2030)
  • Table 370. Rest of Europe Chemotherapy, by Drug Class USD Million (2025-2030)
  • Table 371. MEA Chemotherapy, by Country USD Million (2025-2030)
  • Table 372. MEA Chemotherapy, by Type USD Million (2025-2030)
  • Table 373. MEA Chemotherapy, by Route of Administration USD Million (2025-2030)
  • Table 374. MEA Chemotherapy, by Indication USD Million (2025-2030)
  • Table 375. MEA Chemotherapy, by Distribution Channel USD Million (2025-2030)
  • Table 376. MEA Chemotherapy, by Dosage Form USD Million (2025-2030)
  • Table 377. MEA Chemotherapy, by Drug Class USD Million (2025-2030)
  • Table 378. Middle East Chemotherapy, by Type USD Million (2025-2030)
  • Table 379. Middle East Chemotherapy, by Route of Administration USD Million (2025-2030)
  • Table 380. Middle East Chemotherapy, by Indication USD Million (2025-2030)
  • Table 381. Middle East Chemotherapy, by Distribution Channel USD Million (2025-2030)
  • Table 382. Middle East Chemotherapy, by Dosage Form USD Million (2025-2030)
  • Table 383. Middle East Chemotherapy, by Drug Class USD Million (2025-2030)
  • Table 384. Africa Chemotherapy, by Type USD Million (2025-2030)
  • Table 385. Africa Chemotherapy, by Route of Administration USD Million (2025-2030)
  • Table 386. Africa Chemotherapy, by Indication USD Million (2025-2030)
  • Table 387. Africa Chemotherapy, by Distribution Channel USD Million (2025-2030)
  • Table 388. Africa Chemotherapy, by Dosage Form USD Million (2025-2030)
  • Table 389. Africa Chemotherapy, by Drug Class USD Million (2025-2030)
  • Table 390. North America Chemotherapy, by Country USD Million (2025-2030)
  • Table 391. North America Chemotherapy, by Type USD Million (2025-2030)
  • Table 392. North America Chemotherapy, by Route of Administration USD Million (2025-2030)
  • Table 393. North America Chemotherapy, by Indication USD Million (2025-2030)
  • Table 394. North America Chemotherapy, by Distribution Channel USD Million (2025-2030)
  • Table 395. North America Chemotherapy, by Dosage Form USD Million (2025-2030)
  • Table 396. North America Chemotherapy, by Drug Class USD Million (2025-2030)
  • Table 397. United States Chemotherapy, by Type USD Million (2025-2030)
  • Table 398. United States Chemotherapy, by Route of Administration USD Million (2025-2030)
  • Table 399. United States Chemotherapy, by Indication USD Million (2025-2030)
  • Table 400. United States Chemotherapy, by Distribution Channel USD Million (2025-2030)
  • Table 401. United States Chemotherapy, by Dosage Form USD Million (2025-2030)
  • Table 402. United States Chemotherapy, by Drug Class USD Million (2025-2030)
  • Table 403. Canada Chemotherapy, by Type USD Million (2025-2030)
  • Table 404. Canada Chemotherapy, by Route of Administration USD Million (2025-2030)
  • Table 405. Canada Chemotherapy, by Indication USD Million (2025-2030)
  • Table 406. Canada Chemotherapy, by Distribution Channel USD Million (2025-2030)
  • Table 407. Canada Chemotherapy, by Dosage Form USD Million (2025-2030)
  • Table 408. Canada Chemotherapy, by Drug Class USD Million (2025-2030)
  • Table 409. Mexico Chemotherapy, by Type USD Million (2025-2030)
  • Table 410. Mexico Chemotherapy, by Route of Administration USD Million (2025-2030)
  • Table 411. Mexico Chemotherapy, by Indication USD Million (2025-2030)
  • Table 412. Mexico Chemotherapy, by Distribution Channel USD Million (2025-2030)
  • Table 413. Mexico Chemotherapy, by Dosage Form USD Million (2025-2030)
  • Table 414. Mexico Chemotherapy, by Drug Class USD Million (2025-2030)
  • Table 415. Research Programs/Design for This Report
  • Table 416. Key Data Information from Secondary Sources
  • Table 417. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Chemotherapy: by Type USD Million (2018-2023)
  • Figure 5. Global Chemotherapy: by Route of Administration USD Million (2018-2023)
  • Figure 6. Global Chemotherapy: by Indication USD Million (2018-2023)
  • Figure 7. Global Chemotherapy: by Distribution Channel USD Million (2018-2023)
  • Figure 8. Global Chemotherapy: by Dosage Form USD Million (2018-2023)
  • Figure 9. Global Chemotherapy: by Drug Class USD Million (2018-2023)
  • Figure 10. South America Chemotherapy Share (%), by Country
  • Figure 11. Asia Pacific Chemotherapy Share (%), by Country
  • Figure 12. Europe Chemotherapy Share (%), by Country
  • Figure 13. MEA Chemotherapy Share (%), by Country
  • Figure 14. North America Chemotherapy Share (%), by Country
  • Figure 15. Global Chemotherapy share by Players 2023 (%)
  • Figure 16. Global Chemotherapy share by Players (Top 3) 2023(%)
  • Figure 17. Global Chemotherapy share by Players (Top 5) 2023(%)
  • Figure 18. BCG Matrix for key Companies
  • Figure 19. Novartis AG (Switzerland) Revenue, Net Income and Gross profit
  • Figure 20. Novartis AG (Switzerland) Revenue: by Geography 2023
  • Figure 21. Pfizer Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 22. Pfizer Inc. (United States) Revenue: by Geography 2023
  • Figure 23. Johnson & Johnson Services Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 24. Johnson & Johnson Services Inc. (United States) Revenue: by Geography 2023
  • Figure 25. Bristol-Myers Squibb Company (United States) Revenue, Net Income and Gross profit
  • Figure 26. Bristol-Myers Squibb Company (United States) Revenue: by Geography 2023
  • Figure 27. GlaxoSmithKline PLC (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 28. GlaxoSmithKline PLC (United Kingdom) Revenue: by Geography 2023
  • Figure 29. Eli Lilly and Company (United States) Revenue, Net Income and Gross profit
  • Figure 30. Eli Lilly and Company (United States) Revenue: by Geography 2023
  • Figure 31. F. Hoffmann-La Roche Ltd (Switzerland) Revenue, Net Income and Gross profit
  • Figure 32. F. Hoffmann-La Roche Ltd (Switzerland) Revenue: by Geography 2023
  • Figure 33. Merck & Co. Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 34. Merck & Co. Inc. (United States) Revenue: by Geography 2023
  • Figure 35. Sanofi S.A. (France) Revenue, Net Income and Gross profit
  • Figure 36. Sanofi S.A. (France) Revenue: by Geography 2023
  • Figure 37. Celgene Corporation (United States) Revenue, Net Income and Gross profit
  • Figure 38. Celgene Corporation (United States) Revenue: by Geography 2023
  • Figure 39. Global Chemotherapy: by Type USD Million (2025-2030)
  • Figure 40. Global Chemotherapy: by Route of Administration USD Million (2025-2030)
  • Figure 41. Global Chemotherapy: by Indication USD Million (2025-2030)
  • Figure 42. Global Chemotherapy: by Distribution Channel USD Million (2025-2030)
  • Figure 43. Global Chemotherapy: by Dosage Form USD Million (2025-2030)
  • Figure 44. Global Chemotherapy: by Drug Class USD Million (2025-2030)
  • Figure 45. South America Chemotherapy Share (%), by Country
  • Figure 46. Asia Pacific Chemotherapy Share (%), by Country
  • Figure 47. Europe Chemotherapy Share (%), by Country
  • Figure 48. MEA Chemotherapy Share (%), by Country
  • Figure 49. North America Chemotherapy Share (%), by Country
List of companies from research coverage that are profiled in the study
  • Novartis AG (Switzerland)
  • Pfizer Inc. (United States)
  • Johnson & Johnson Services Inc. (United States)
  • Bristol-Myers Squibb Company (United States)
  • GlaxoSmithKline PLC (United Kingdom)
  • Eli Lilly and Company (United States)
  • F. Hoffmann-La Roche Ltd (Switzerland)
  • Merck & Co. Inc. (United States)
  • Sanofi S.A. (France)
  • Celgene Corporation (United States)
Additional players considered in the study are as follows:
LEO Pharma A/S (Denmark) , Bausch Health Companies Inc. (Canada) , Sun Pharmaceutical Industries Ltd. (India) , Aurobindo Pharma (India) , Hikma Pharmaceuticals PLC (U.K.),
Select User Access Type

Key Highlights of Report


May 2024 245 Pages 52 Tables Base Year: 2023 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Chemotherapy Market Quantitative research analysis
Global Chemotherapy Market Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

The standard version of the report profiles players such as Novartis AG (Switzerland), Pfizer Inc. (United States), Johnson & Johnson Services Inc. (United States), Bristol-Myers Squibb Company (United States), GlaxoSmithKline PLC (United Kingdom), Eli Lilly and Company (United States), F. Hoffmann-La Roche Ltd (Switzerland), Merck & Co. Inc. (United States), Sanofi S.A. (France) and Celgene Corporation (United States) etc.
The Study can be customized subject to feasibility and data availability. Please connect with our sales representative for further information.
"Rising demand for personalized medicines" is seen as one of major influencing trends for Chemotherapy Market during projected period 2023-2030.
The Chemotherapy market study includes a random mix of players, including both market leaders and some top growing emerging players. Connect with our sales executive to get a complete company list in our research coverage.

Know More About Global Chemotherapy Market Report?

Have a Query? Click Here

Other Related Reports

Prostate Cancer Nuclear Medicine Diagnostics Comprehensive Study by Type (Single-Photon Emission Computed Tomography (SPECT), Positron Emission Tomography (PET)), Application (Hospitals, Clinics, Oth...
$ 3800
Smart Medicine Bottles Comprehensive Study by Type (Smart Pill Boxes, Smart Pill Bottles, Others), Indication (Dementia, Cancer Management, Diabetes Care, Others), End Use (Home Care Settings, Specia...
$ 3450
Home Health Hub Comprehensive Study by Type (Standalone Hubs, Smartphone-based hubs, Services (Remote Patient Monitoring Services, Support & Maintenance Services)), Patient Monitoring (High-acuity Pa...
$ 3750
Urinary Self Catheter Comprehensive Study by Type (Intermittent Catheter, Uncoated Intermittent Catheters, Coated Intermittent Catheters, Antimicrobial intermittent catheters, Hydrophilic intermitten...
$ 3450
PACS Systems Comprehensive Study by Type (Radiology PACS, Cardiology PACS, Pathology PACS, Ophthalmology PACS, Orthopedics PACS, Oncology PACS, Dermatology PACS, Neurology PACS, Endoscopy PACS, Women...
$ 3650
Artificial Intelligence (AI) in Drug Discovery Comprehensive Study by Application (Immuno-oncology, Neurodegenerative Diseases, Cardiovascular Diseases, Metabolic Diseases, Other Applications), Techn...
$ 3800